November 7th Options Now Available For Regeneron Pharmaceuticals (REGN)

For investors considering Regeneron Pharmaceuticals (REGN), the article outlines two options strategies: selling a $560 cash-secured put offers a 3.75% premium (31.80% annualized) with a 61% probability of expiring worthless, effectively reducing the cost basis to $539 for potential acquisition. Alternatively, a covered call strategy at the $580 strike yields a 4.90% premium (41.52% annualized) if it expires worthless, or a 7.04% return by November 7th if shares are called away, with a 48% probability of expiring worthless. Both approaches capitalize on REGN's implied volatility (41-42%), which is marginally higher than its 12-month historical volatility (40%), to generate enhanced yield.

Analysis

The options market for Regeneron Pharmaceuticals (REGN) presents two distinct yield-enhancement strategies based on current pricing and volatility metrics. For investors seeking to initiate a position, selling a cash-secured put at the $560 strike offers a $21.00 premium, which lowers the effective cost basis to $539.00 per share—a notable discount from the current price of $567.85. Analytical data suggests a 61% probability of this out-of-the-money put expiring worthless, which would result in a 3.75% return on the cash commitment, or an annualized yield of 31.80%. For existing shareholders, a covered call strategy at the $580 strike provides a $27.80 premium. This approach yields a total return of 7.04% by the November 7th expiration if the stock is called away, or a 4.90% premium boost (41.52% annualized) if the option expires worthless, an event with a 48% probability. Critically, the implied volatility in these options (41-42%) is slightly elevated compared to the stock's trailing twelve-month actual volatility of 40%, suggesting that option premiums are marginally rich relative to recent historical price action, a condition that favors option sellers.

Key Decisions for Investors

• Investors bullish on REGN but seeking a lower entry point could consider selling the $560 cash-secured put to either acquire shares at an effective cost of $539 or generate a 31.80% annualized yield on the cash collateral if the option expires worthless.
• Current REGN shareholders aiming to generate income could evaluate selling the $580 covered call to collect a premium representing a 41.52% annualized yield, but must accept that this strategy caps upside potential and creates a 7.04% maximum return by expiration if shares are called away.
• Given that implied volatility of 41-42% is slightly above historical volatility of 40%, the environment is incrementally favorable for sellers of options premium, though investors must weigh the probabilities of success against the respective risks of share assignment or capped gains.